Leveraging cutting-edge
scientific research and technology
Leveraging cutting-edge
scientific research and technology
Who we are
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.
Our mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our approach
By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews
DMT is a psychoactive alkaloid present in Ayahuasca, a hallucinogenic brew traditionally used by indigenous communities in South America.
Meet Viridia, the ATAI unit exploring ayahuasca-based treatments for mental illness
Can ayahuasca, a psychoactive brew used traditionally in South America, be used to treat depression and other mental illnesses? Biotech builder ATAI Life Sciences is setting up a subsidiary to find out: Viridia Life Sciences.
After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought to ban
Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day
ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews
DMT is a psychoactive alkaloid present in Ayahuasca, a hallucinogenic brew traditionally used by indigenous communities in South America.
INSIGHT NETWORK: Diving deep with Matthew W. Johnson
In this episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr. Matthew
INSIGHT NETWORK: A conversation with Robin Carhart-Harris
In the inaugural episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr.
YPO Psychedelic Medicine for Mental Health Group – A Conversation with Christian Angermayer
Join Richard Simon, Chair at YPO (Young Presidents Organization) Psychedelic Medicines for Mental Health Group,
INSIGHT NETWORK: Diving deep with Matthew W. Johnson
In this episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr. Matthew
Vast experience
and great access to deal flow
Vast experience
and great access to deal flow
Work with us
to improve the lives of millions of people
Work with us
to improve the lives of millions of people
WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.
Join the ATAI #InsightNetwork
Join the ATAI #InsightNetwork
Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space